|2026年5月28日星期四| NO.1迪哲医药舒沃哲用于单药一线治疗EGFR exon20ins非小细胞肺癌的新药上市申请获受理 5月27日,迪哲医药公告自主研发的新型肺癌靶向药舒沃哲(通用名:舒沃替尼片)新增适应证新药上市申请(NDA)获国家药品监督管理局(NMPA)药品审评中心(CDE)正式受理,并纳入优先审评程序,用于表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性...
Source Link|2026年5月28日星期四| NO.1迪哲医药舒沃哲用于单药一线治疗EGFR exon20ins非小细胞肺癌的新药上市申请获受理 5月27日,迪哲医药公告自主研发的新型肺癌靶向药舒沃哲(通用名:舒沃替尼片)新增适应证新药上市申请(NDA)获国家药品监督管理局(NMPA)药品审评中心(CDE)正式受理,并纳入优先审评程序,用于表皮生长因子受体(EGFR)20号外显子插入突变的局部晚期或转移性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.